C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting Biotech Investing
Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities Biotech Investing
neffy® Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions Biotech Investing
Republic Technologies Engages Fireblocks to Bolster Institutional-Grade Risk Management Medical Device Investing
Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds Biotech Investing
Incyte Announces Additional FDA Approval of Opzelura® Cream in Children Ages 2-11 with Atopic Dermatitis Biotech Investing
